This is the authors' abstract. We don't add key points for this paper.
Fexuprazan demonstrated protective effects against NSAID-induced small intestinal injury, while esomeprazole did not. Its ability to preserve intestinal barrier integrity, modulate inflammatory responses, and restore gut microbiota composition highlights its therapeutic potential in NSAID-induced enteropathy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: